Our innovative structured secondaries approach provides exposure to the best in venture-stage investment opportunities, combining meaningful downside protection and uncapped upside return potential. Our goal is to optimize risk-adjusted returns across the full range of VC outcomes.
Downside protection and
Access to compelling
Venture capital structured secondaries
Our flagship series, with past vintages in 2018 and 2021, is now on its third fund and has repeatedly demonstrated the success of our differentiated global approach to VC investing.
Secondaries in life sciences
This fund, which launched in 2021, applies our structured secondaries approach to investments in health care, med-tech and life sciences–related technology.
Southeast Asia opportunities
This fund, which launched in 2022, applies our structured secondaries approach to VC investments solely in Southeast Asia.
For more information about our strategies, please contact us here.